Welcome to Xention
Xention is developing novel therapies for the treatment of atrial fibrillation using its proprietary platform of ion channel drug discovery and development.
The Company is developing drug candidates that modulate two novel, but well characterised, ion channels and expects to develop breakthrough products in this area of huge unmet medical need.
In addition, we have established alliances with major pharmaceutical companies in areas outside our core interests.
Xention commences first phase 2 study of XEN-D0103 in atrial fibrillation
Xention awarded £1.4m from Technology Strategy Board to develop new medicines for atrial fibrillation